A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells

Melissa A Gray; Ran N Tao; Sandra M DePorter; David A Spiegel; Brian R McNaughton

doi:10.1002/cbic.201500591

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells

Chembiochem. 2016 Jan;17(2):155-8. doi: 10.1002/cbic.201500591. Epub 2015 Dec 10.

Authors

Melissa A Gray¹, Ran N Tao², Sandra M DePorter¹, David A Spiegel², Brian R McNaughton^{3

4}

Affiliations

¹ Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA.
² Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT, 06511, USA.
³ Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA. brian.mcnaughton@colostate.edu.
⁴ Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CT, 80523, USA. brian.mcnaughton@colostate.edu.

Abstract

We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.

Keywords: HER2; activation immunotherapeutic; breast cancer; immunotherapy; nanobody.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Breast Neoplasms / drug therapy*
Cell Line, Tumor
Female
Genes, erbB-2* / drug effects
Humans
Immunotherapy
Molecular Structure

Substances

Antibodies, Monoclonal

Abstract

Publication types

MeSH terms

Substances

Grants and funding